US EditionPublished • loading... • Updated
Ozempic Cuts Heart Disease Risk by 20% Regardless of Weight Loss
- On October 22 researchers reported semaglutide reduced major adverse cardiovascular events regardless of weight loss in the SELECT trial of over 17,000 adults aged 45 and over, published in The Lancet journal.
- Building on earlier 20% findings, researchers re‑examined the SELECT trial to test if cardiovascular benefits were due to weight loss or other mechanisms, using prespecified data presented last year.
- The team found waist circumference reduction mediated an estimated 33 per cent of the benefit on heart events, with each 5‑centimetre drop linked to about a 9 per cent lower risk.
- Clinicians said researchers suggest Wegovy use should not be limited to severely obese patients; last year the UK medicines regulator approved it and the NHS in England will roll out jabs to 240,000 people.
- Future trials should explore the roles of blood vessel lining, blood pressure, blood sugar, inflammation, and responses by ethnicity and sex, as two thirds of the benefit remain unexplained.
Insights by Ground AI
26 Articles
26 Articles
The findings, published in the scientific journal The Lancet, suggest that such drugs could have broader health benefits for patients.
Coverage Details
Total News Sources26
Leaning Left9Leaning Right4Center7Last UpdatedBias Distribution45% Left
Bias Distribution
- 45% of the sources lean Left
45% Left
L 45%
C 35%
R 20%
Factuality
To view factuality data please Upgrade to Premium
